An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread

Part of paid clinical trials in Duarte, California.

Sponsor
Bristol-Myers Squibb
Study ID
NCT03459222
Phase
PHASE1/PHASE2
Status
Completed

Conditions

  • Advanced Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Relatlimab — BIOLOGICAL
    Specified dose on specified days
  • Nivolumab — BIOLOGICAL
    Specified dose on specified days
  • BMS-986205 — DRUG
    Specified dose on specified days
  • Ipilimumab — BIOLOGICAL
    Specified dose on specified days

Study Details

The purpose of this study is to demonstrate the safety and preliminary activity with triple combinations of relatlimab in combination with nivolumab and BMS-986205, or in combination with nivolumab and ipilimumab in immunotherapy-naive and pretreated populations across select advanced tumor types.

Key Dates

Start date
May 30, 2018
Status verified
Mar 2026
Primary completion
Feb 19, 2025
Completion
Feb 19, 2025

Study Design

Enrollment
229 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Arm A
    Relatlimab + Nivolumab + BMS-986205
  • Experimental: Arm B
    Relatlimab + Nivolumab + Ipilimumab

Primary Outcome Measure

Number of Participants With Grade 3/Grade 4 Laboratory Test Results [ Time Frame: From first dose (Day 1) and within 30 days of last dose of study therapy (up to approximately 69 months) ]

Locations (5)

FacilityCityStateZIPSite coordinators
Local Institution - 0006DuarteCalifornia91010-
Local Institution - 0003AuroraColorado80045-
Local Institution - 0004BaltimoreMaryland21231-
Local Institution - 0005St LouisMissouri63110-
Local Institution - 0001GermantownTennessee38138-

Related coverage on Hipa.ai

Find similar trials in Duarte, CA

Related Studies